{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_dda7af", "batch_size": 200, "batch_pos": 110, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 2, "answer": "no", "rationale": "The segment uses neutral language without high-potency verbs, metaphors, or alert phrases.", "method": "llm_batch", "batch_id": "batch_2_933422", "batch_size": 200, "batch_pos": 73, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 3, "answer": "no", "rationale": "The segment describes a plan ('plans to launch'), not realised impact, and lacks a moderate verb + scale pattern.", "method": "llm_batch", "batch_id": "batch_3_c18303", "batch_size": 200, "batch_pos": 4, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_ee5be2", "batch_size": 200, "batch_pos": 194, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 5, "answer": "no", "rationale": "The segment reports a plan for a human trial and ability to 'respond very quickly,' a preparedness/capability cue lacking an explicit link to present public safety.", "method": "llm_batch", "batch_id": "batch_5_591551", "batch_size": 200, "batch_pos": 189, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
